التفاصيل البيبلوغرافية
| العنوان: |
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy |
| المؤلفون: |
Sliwa, Karen, Meer, Peter, Petrie, Mark C., Frogoudaki, Alexandra, Johnson, Mark R., Hilfiker‐Kleiner, Denise, Hamdan, Righab, Jackson, Alice M., Ibrahim, Bassem, Mbakwem, Amam, Tschöpe, Carsten, Regitz‐Zagrosek, Vera, Omerovic, Elmir, Roos‐Hesselink, Jolien, Gatzoulis, Michael, Tutarel, Oktay, Price, Susanna, Heymans, Stephane, Coats, Andrew J.S., Müller, Christian |
| المصدر: |
European Journal of Heart Failure; Apr2021, Vol. 23 Issue 4, p527-540, 14p, 1 Color Photograph, 4 Diagrams |
| مصطلحات موضوعية: |
PERIPARTUM cardiomyopathy, HEART failure, ARRHYTHMOGENIC right ventricular dysplasia, CARDIOMYOPATHIES, CONGENITAL heart disease, MYOCARDIUM |
| الشركة/الكيان: |
EUROPEAN Society of Cardiology |
| مستخلص: |
This position paper focusses on the pathophysiology, diagnosis and management of women diagnosed with a cardiomyopathy, or at risk of heart failure (HF), who are planning to conceive or present with (de novo or previously unknown) HF during or after pregnancy. This includes the heterogeneous group of heart muscle diseases such as hypertrophic, dilated, arrhythmogenic right ventricular and non‐classified cardiomyopathies, left ventricular non‐compaction, peripartum cardiomyopathy, Takotsubo syndrome, adult congenital heart disease with HF, and patients with right HF. Also, patients with a history of chemo‐/radiotherapy for cancer or haematological malignancies need specific pre‐, during and post‐pregnancy assessment and counselling. We summarize the current knowledge about pathophysiological mechanisms, including gene mutations, clinical presentation, diagnosis, and medical and device management, as well as risk stratification. Women with a known diagnosis of a cardiomyopathy will often require continuation of drug therapy, which has the potential to exert negative effects on the foetus. This position paper assists in balancing benefits and detrimental effects. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Heart Failure is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder